KariyerYatırımcı ilişkileriHakkımızda
  1. Siemens Healthineers Türkiye
  2. Digital Health Solutions
  3. Digital portfolio overview
  4. Supporting diagnostic and therapeutic decision-making
  5. AI-Pathway Companion

AI-Pathway CompanionActionable insights for personalized care

  • Benefits
  • Clinical use
  • Bulletin
Contact Us

Benefits

Patient consultation

Patient consultation

AI-Pathway Companion1, a CE marked4 clinical decision support solution, enables personalized and standardized care along care pathways in oncology, cardiology3 and infectious diseases3. The intelligent clinical decision support solution aims to facilitate diagnosis and therapeutic decisions with a clear goal: improving patient outcomes along disease-specific pathways10.

At a glance, the solution shows the patient’s relevant clinical history, current patient status, diagnostic images and results from the pathological reports, directly on hand, eliminating the need to access information from multiple databases or files. With key information readily in head, you are prepared for each patient discussion or consultation with other specialists. 

Leveraging AI technologies to provide further insights for you and your patients , the AI-Pathway Companion compares the patient´s clinical status against the current guidelines6 and, through a decision diagram, shows you where your patient is and the options for the next steps in diagnosis and therapy. You can think of it as a clinical GPS system where patients are at the center of it all.

The next-level clinical decision support solution

Meet your new go-to source of information that supports personalized diagnostic and therapeutic decisions along the entire clinical pathway.

Clinical use

AI-Pathway Companion...

  • ... aggregates, correlates, and visualizes relevant patient-specific information along the prostate cancer pathway2 and other disease pathways3
  • ... enables automatic patient-specific mapping along clinical pathways using evidence-based guidelines2, 5, 6, 10
  • ... facilitates objective decision-making by multi-disciplinary experts on correlated patient data and
    preferences2, 5
  • ... offers transparent insights into time to diagnosis and treatment8
ai pathway companion interface

“One of the goals as associate chief medical officer is for the healthcare system as a whole to decrease unjustified variations and improve outcomes, and clinical decision support has the opportunity to do that.”11

Mark Wakefield, MD

Urologist at Missouri University Health Care 

Bulletin

Here you will find latest news and publications on the AI-Pathway Companion.

Clinical decision support: 6 questions with Prof. Lars Budäus 

The Martini-Klinik at UKE Hamburg is a world renown center for prostate cancer care. We are talking to one of their Lead Urologists, Prof. Lars Budäus, about clinical decision support and how it can help to address the challenges of modern patient management and process improvement.

1

AI-Pathway Companion applications are not commercially available in all countries. Their future availability cannot be guaranteed. 

2

AI-Pathway Companion Prostate Cancer is not commercially available in all countries. Its future availability cannot be guaranteed.

3

AI-Pathway Companion Lung Cancer, AI-Pathway Companion Breast Cancer, AI-Pathway Companion Coronary Artery Disease, and AI-Pathway Companion Infectious Diseases are under development and not commercially available. Its future availability cannot be ensured.

4

AI-Pathway Companion Prostate Cancer VA10B/VC10A is CE-compliant in accordance with Directive 93/42/EEC.

5

AI-Pathway Companion Prostate Cancer VA10B/VC10A supports prostate cancer adenocarcinoma cases only. 

6

AI-Pathway Companion Prostate Cancer VA10B/VC10A supports prostate cancer guidelines by NCCN and EAU only.

7

This function is supported by AI-Pathway Companion Connector.

8

This function is supported by AI-Pathway Companion Analytics.

9

This function is supported by AI-Pathway Companion Prostate Cancer.

10

Prerequisite: “All data is available as required per guideline.”; Feature dependent on quality of input data.

11

The statements by Siemens Healthineers’ customers described herein are based on results that were achieved in the customer's unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.

12

Physician is employed by an institution that receives financial support from Siemens Healthineers for collaborations.

13

NLP supported languages: English, German, Dutch 

14Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. ACS Journal, 12 September 2018. doi: 10.3322/caac.21492